Celsion is committed to the development of efficient, effective and targeted therapies for the treatment of cancer. Our method is an elegant approach that delivers high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the side-effects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications.
The focus of our current clinical development efforts is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, a frequently-used and proven cancer drug. The ThermoDox® program offers a “pipeline within a product”, with the potential for groundbreaking advancements in the treatment of multiple tumor indications that represent major market opportunities worldwide. In addition, by pairing our novel technology with a proven, approved drug, we have the opportunity to significantly improve upon existing treatment options without the level of risk inherent in the development of new chemical entities.
We are currently nearing the completion of our global Phase III HEAT study of ThermoDox® in hepatocellular carcinoma (HCC or primary liver cancer). Due to the growing incidence of Hepatitis B and C in developing countries, HCC is projected to become the most prevalent cancer globally by 2020. We have designed the HEAT Study to support approval in multiple markets worldwide, and are seeking global partnerships to maximize the commercial potential of this near-term product opportunity.
To support growth over the long-term, we are evaluating ThermoDox® in additional indications, including recurrent chest wall breast cancer, colorectal liver metastases and bone metastases. Beyond these indications, ThermoDox® holds promise in a wide variety of other tumor indications for which doxorubicin is widely used. We also continue to invest in our liposomal technology, developing proprietary formulations of other marketed chemotherapeutics.
Our strategy and focus is driven by our commitment to deliver innovative and effective treatments for cancer patients. With our expertise in oncology, experienced leadership team, network of world-class partners and infrastructure, we are building a fully integrated oncology company that can address emerging needs in cancer treatment and improve the lives of patients.